Related Experiment Video

Updated: Jan 10, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.8K

Reply: When locoregional therapy fails, how soon should we pivot

Karim Seif El Dahan1, Nicole E Rich, Amit G Singal

  • 1Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.

Hepatology (Baltimore, Md.)
|November 26, 2025
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K

Related Experiment Videos

Last Updated: Jan 10, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.8K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

Articles linked to this work by shared authors, journal, and citation graph.

Increased MASH-associated liver cancer in younger demographics.

Hepatology communications·2025

Alcohol-Related Liver Disease, Followed by Metabolic Dysfunction-Associated Steatotic Liver Disease, Emerges as the Fastest-Growing Aetiologies for Primary Liver Cancer in the United States.

Alimentary pharmacology & therapeutics·2025

Do Risk Factors for HCC Impact the Association of CT/MRI LIRADS Major Features With HCC? An Individual Participant Data Meta-Analysis.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes·2024

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.

Clinical and molecular hepatology·2024

Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel.

Hepatology (Baltimore, Md.)·2024

Global Trend of MASH-associated Liver Cancer: A Systematic Analysis From the Global Burden of Disease 2021.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2024

A First-in-Human study of AHB-137, an unconjugated antisense oligonucleotide, in healthy subjects and patients with chronic hepatitis B.

Hepatology (Baltimore, Md.)·2026

Hepatocyte hnRNPK preserves mitochondrial integrity to restrain liver injury and fibrosis.

Hepatology (Baltimore, Md.)·2026

Liver-on-a-Chip: Applications for clinical modeling of liver disease using microscale systems.

Hepatology (Baltimore, Md.)·2026

BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma.

Hepatology (Baltimore, Md.)·2026

With no lysine kinase 1 in hepatic stellate cells promotes mouse and human liver fibrosis through glycolytic triosephosphate isomerase 1.

Hepatology (Baltimore, Md.)·2026

Nucleos(t)ide withdrawal versus nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B trial).

Hepatology (Baltimore, Md.)·2026

SHORT- VERSUS LONG-COURSE RADIATION IN TOTAL NEOADJUVANT THERAPY FOR LOCALLY ADVANCED RECTAL CANCER: A PROPENSITY-MATCHED NATIONAL CANCER DATABASE ANALYSIS.

Diseases of the colon and rectum·2026

Multiple Painful Papules on the Arm: A Clue to Reed Syndrome.

Cureus·2026

Relationship between radiosensitivity of peripheral blood lymphocytes, breast cancer cells, and breast cancer stem cells in patients with breast cancer.

Biochemistry and biophysics reports·2026

A genome-wide association study on radiation induced fibrosis in breast cancer patients.

Clinical and translational radiation oncology·2026

Radiation dose comparison of photon-counting breast CT and mammography: A phantom study.

European journal of radiology open·2026

Safety profile of therapeutic radiopharmaceuticals for bone metastases pain palliation: evidence from a systematic literature review.

Nuclear medicine communications·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us